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Abstract. Colorectal cancer (CRC), which is one of the most
common malignancies worldwide, results from an accumulation of genetic and epigenetic modifications including DNA
methylation. Neurotensin (NTS), a hormone localized to the
gut and central nervous system, mediates its physiological and
pathological effects, including growth stimulation for a variety
of cancers, through three distinct NTS receptors (NTSRs).
Most NTS functions are mediated through the high-affinity
receptor NTSR1, and expression of NTSR1 is increased in
many cancers including CRC. In this study, we investigated
the expression profiles and cellular functions of the NTSRs,
especially NTSR1, in CRC cells. We showed that expression
levels for NTS and NTSR1 varied, that NTSR2 expression was
not detectable and that NTSR3 was consistently expressed
in all CRC cell lines examined. Treatment with the demethylating agent, 5-aza-2'-deoxycytidine, augmented levels of
NTSR1/2 in Caco2 and DLD1 cells, which have little or no
transcripts for NTSR1/2 suggesting that DNA methylation
suppresses NTSR1/2 expression. In addition, we demonstrated that knockdown of NTSR1 decreased cell growth and
migration in HCT116 and HT29 cells. Finally, we showed
that treatment with SR48692, an antagonist of NTSR1, also
inhibited cell proliferation and migration in the CRC cells.
Our findings identify promoter methylation as an important
process regulating the differential expression or silencing
of NTSR1/2 in CRC cells. Moreover, inhibition of NTSR1
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repressed tumorigenic effects in CRC cells, suggesting that
NTSR1 may be used as a therapeutic target for CRC.
Introduction
Colorectal cancer (CRC) is one of the most common malignancies in the United States and worldwide (1). Genetic
alterations, specifically gene mutations implicated in CRC
tumorigenesis, lead to a gain of oncogene function and loss of
tumor suppressor gene function (2). Epigenetic modifications,
particularly DNA methylation in selected gene promoters,
are also recognized common molecular alterations in human
tumors (2,3).
Neurotensin (NTS), a tridecapeptide mainly distributed
along the gastrointestinal (GI) tract, functions to decrease
gastric motility, to increase pancreaticobiliary secretion, to
facilitate fatty acid absorption, and to increase proliferation
of normal intestinal mucosa (4-6). In addition to these physiologic effects, NTS influences intestinal inflammation and
promotes the growth of cancers, including breast, prostate,
pancreas, lung and cancers of the GI tract (4,7,8). The effects of
NTS are exerted primarily by its G protein-coupled receptors:
the high-affinity NTS receptor 1 (NTSR1), and the lowaffinity NTSR2 (7,8). NTSR3/sortilin, a single transmembrane
receptor, also binds NTS and contributes to the diversity of
effects on multiple tissues (7,8).
The properties of NTS are predominantly mediated
through NTSR1, and this neuropeptide-receptor complex
is deregulated during cancer progression (8,9). Although
increased expression of NTSR1 has been identified in certain
cancer types, such as colon and neuroendocrine tumors
(NETs) (10-16), the molecular mechanisms regulating NTSRs
expression have not been clarified. Recently, we reported that
promoter methylation is an important molecular process that
regulates the differential expression of NTSR1 and silences
NTSR2 in NET cells, and that silencing of NTSR1 suppressed
the oncogenic effects of NTS (16). In the current study, we
analyzed the endogenous expression of NTS signaling
components, the transcriptional change of NTSR genes mediated by a demethylating agent, and the methylation status of
their promoters in CRC cell lines. Importantly, we show that
inhibition of NTSR1 by either gene knockdown or treatment
with an NTSR1 inhibitor decreases the growth and migration
of CRC cells.
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Materials and methods
Cell lines, reagents and siRNA transfection. The human
CRC cell lines KM12c, Caco2, DLD1, HT29, HCT116,
and SW480 were used in these studies. Cell lines were
authenticated in February and May 2016 at Genetica DNA
Laboratories (Cincinnati, OH). KM12c cells were kindly
provided by Dr Isaiah J. Fidler (M.D. Anderson Cancer
Center, Houston, TX, USA); other cell lines were obtained
from American Type Culture Collection (Manassas, VA,
USA). KM12c cells were cultured in MEM supplemented
with 10% fetal bovine serum (FBS), 1% sodium pyruvate,
1% non-essential amino acids and 2% MEM essential vitamins. Caco2 cells were incubated in MEM supplemented
with 15% FBS, 1% sodium pyruvate and 1% non-essential
amino acids. DLD1 cells were grown in RPMI-1640 with
10% FBS. HT29 and HCT116 cells were maintained in
McCoy's 5A medium supplemented with 10% FBS. SW480
cells were cultured in DMEM with 10% FBS. Cells were
maintained at 37˚C in a humidified 5% CO2 incubator. The
DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine
(5-aza-CdR), and a selective inhibitor for NTSR1, SR48692,
were purchased from Sigma-Aldrich (St. Louis, MO, USA)
and dissolved in dimethyl sulfoxide (DMSO). Transfections
with non-targeting control and SMARTPool NTSR1 siRNA
(Dharmacon, Lafayette, CO, USA) were performed using
Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA)
as previously described (16).
RNA isolation, reverse transcription-PCR (RT-PCR) and
quantitative reverse transcription-PCR (RT-qPCR) analysis.
Total RNA isolation, cDNA synthesis and RT-PCR analysis
were carried out as previously described (16,17). Briefly,
RT-PCR reactions for NTS signaling elements were performed
using cDNA synthesized from 1 µg of total RNA from CRC
cells, HotStarTaq DNA Polymerase (Qiagen, Valencia, CA,
USA) and primers as follows: NTSR1 F, 5'-TCATCGC
CTTTGTGGTCTGCT-3', and NTSR1 R, 5'-TGGTTGCT
GGACACGCTGTCG-3', 33 cycles; NTSR2 F, 5'-GTCTCC
TCAGCTTCATCGTAT-3', and NTSR2 R, 5'-TCCCCAA
AGCCTGAAGCTGTA-3', 40 cycles; NTSR3 F, 5'-AGAA
TGGTCGAGACTATGTTG-3', and NTSR3 R, 5'-AAG
AGCTATTCCAAGAGGTCC-5', 33 cycles; NTS F, 5'-GAT
GATGGCAGGAATGAAAATCCAG-3', and NTS R, 5'-GTT
GAAAAGCCCTGCTGTGACAGA-3', 40 cycles; β -actin
F, 5'-TCACCAACTGGGACGACATG-3', and β -actin
R, 5'-ACCGGAGTCCATCACGATG-3', 28 cycles; IL-8
F, 5'-CATGACTTCCAAGCTGGCCG-3', and IL-8 R, 5'-AAT
TTTTTTATGAATTCTCAGCCCTC-3', 33 cycles; cyclin D1
F, 5'-ATGTGTGCAGAAGGAGGTCC-3' and cyclin D1
R, 5'-CTTAGAGGCCACGAACATGC-3', 38 cycles. Cycling
conditions for the reactions were: initial melting at 95˚C for
15 min, followed by the above described numbers of cycles at
94˚C for 30 sec, 55˚C for 30 sec and 72˚C for 45 sec and a final
extension of 10 min at 72˚C (MJ Mini Thermal Cycler,
Bio-Rad, Irvine, CA, USA). The PCR products were analyzed
on a 2% agarose gel and visualized with the Alpha Innotech
Imaging system (Alpha Innotech Corp., San Leandro, CA,
USA). RT-qPCR was carried out using TaqMan kits (Applied
Biosystems, Foster City, CA, USA) under StepOnePlus
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Real‑Time PCR System (Applied Biosystems) as previously
described (16), according to the manufacturer's protocol.
Methylation analysis. The methylation status of the NTSR1
and NTSR2 promoters was determined by methylation-specific
PCR (MSP) and bisulfite sequencing (BS) analyses as previously described (16,17). In brief, PCR with 35 cycling reactions
was performed using bisulfite-modified genomic DNA,
HotStarTaq DNA Polymerase (Qiagen) and primers as follows:
NTSR1 MSP methyl (M) F, 5'-TTGGAATTCGTGGTA
AGC-3', and NTSR1 MSP M R, 5'-GTCTCAAACGAAA
ACCGATA-3'; NTSR1 MSP unmethyl (U) F, 5'-TATTTG
GAATTTGTGGTAAGT-3', and NTSR1 MSP U R, 5'-ATCT
CA A ACA A A A ACCA ATA A AC-3'; N TSR 2 MSP M
F, 5'-GTGGAGTTCGGTTTAATTC-3', and NTSR2 MSP M
R 5'-ACTACCCGAAATCTAAACG-3'; NTSR2 MSP U
F, 5'-GGTGGAGTTTGGTTTAATTT-3', and NTSR2 MSP U
R, 5'-CACTACCCAAAATCTAAACA-5'; NTSR1 BS
F, 5'-TTGTGGATATTTAGGAGTGGG-3' and NTSR1 BS
R, 5'-CTCCAAAAAACCAAAATTCC-3'; NTSR2 BS
F, 5'-TGTTGGGAAAGTTTTTTTTAAG-3' and NTSR2 BS
R, 5'-AAACACCTCCTCTTCTCTAAAAA-3'. The PCR
products for MSP were visualized as indicated above. For BS,
PCR products were cloned into the TOPO TA cloning vector
(Invitrogen) and the plasmids from individual bacterial colonies were sequenced.
Cell proliferation. Equal numbers of HCT116 and HT29 cells
were seeded in 24-well plates. Proliferation of cells transfected
with siRNA or treated with SR48692 was assessed at 48 and
96 h after seeding by direct cell counting using a Beckman
Coulter Cell Viability Analyzer (Beckman-Coulter, Fullerton,
CA, USA).
Western blot analysis. Western blot analysis was done as
previously described (16). The antibodies for rabbit polyclonal
NTSR1 (PA3-214, 1:2500 dilution) and rabbit monoclonal
cyclin D1 (2261-1, 1:5000 dilution) were purchased from
Thermo Fisher Scientific (Rockford, IL, USA) and Epitomics
(Burlingame, CA), respectively. The rabbit polyclonal IL-8
(ab106350, 1:500 dilution) and mouse monoclonal anti-β‑actin
(A5316, 1:5000 dilution) antibodies were obtained from Abcam
(Cambridge, MA, USA) and Sigma-Aldrich, respectively.
Wound-healing migration assay. A wound-healing migration
assay was performed, using the Ibidi Culture Insert (Ibidi,
Munich, Germany), with control and NTSR1 knockdown
HCT116 or HT29 cells. The wounded monolayers, generated
by removal of the insert, which provides a cell-free gap, were
maintained for the indicated time periods. Phase-contrast
microscopic images were acquired using a Nikon Eclipse Ti
microscope and NIS Elements software (Nikon, Melville, NY,
USA). The data are the quantified gap distance.
Luciferase reporter assays. HCT116 and HT29 cells, seeded
in 24-well plates, were transiently transfected with the IL-8
reporter (0.4 µg) and the Renilla luciferase reporter (0.05 µg)
using Lipofectamine 2000 (Invitrogen) according to the
manufacturers' instructions. For the NTSR1 inhibitor treatments, CRC cells were treated with SR48692 (0, or 10 µM)
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Figure 1. Analysis of NTS signaling components in endogenous or 5-aza-CdR treated CRC cell lines. (A) Expression analysis of mRNA levels for NTS, NTSRs
and β -actin in six CRC cells by RT-PCR. (B) Expression analysis of mRNA levels for NTS components and β -actin in DLD1 and Caco2 cells treated with 0,
2.5 or 10 µM 5-aza-CdR by RT-PCR. Media were replaced every 24 h for 4 days. (C) Quantitative RT-PCR analysis (RT-qPCR) for DLD1 and Caco2 cells
treated with 5-aza-CdR. Presented data are the relative amounts of mRNA calculated by the ∆∆Cq method performed in quadruplicate, with standard deviation
(SD) shown. *P<0.05 indicates a significant difference in mRNA levels between the inhibitor and vehicle (0 µM) treatments; GAPDH was the internal control.

one day after transfection. Luciferase activity was measured
from cell lysates using a Dual-Luciferase Reporter Assay
System (Promega, Madison, WI) through Sirius Luminometer
(Berthold Detection Systems, Pforzheim, Germany) according
to the manufacturers' protocols.
Transwell migration assay. Cell migration assessments
were performed using 8.0 µm pore size Transwell filter
inserts (Corning Inc., Corning, NY, USA) coated with
15 µg/ml type I collagen in 24-well plates. Briefly, HCT116
cells, serum-starved for 24 h, were trypsinized, washed twice
and resuspended in serum-free media supplemented with 0.1%
BSA. For replicates, equivalent cell numbers were placed in
the upper chamber, while the lower chamber was filled with
the same serum-free media containing SR48692 (either 0 or
10 µM). The cells were incubated in the Transwell chambers
for 20 h at 37˚C. After removing the non-migrated cells from
the upper surface of the membrane, cells on the lower surface
were fixed with methanol and stained with 0.5% crystal violet.
Migration was determined by counting cell numbers in four
random fields per membrane under a Nikon Eclipse 80i microscope and NIS Elements software (Nikon) at x10.
Statistical analysis. Means and standard deviations for
triplicate or quadruple samples were calculated, and graphic
representations summarize mRNA levels of NTSR1 and
NTSR2, number of counted cells, migration distance, IL-8
luciferase activity and migrated cell number. Comparisons
between groups were performed using two-sample t-test
or analysis of variance, as indicated, with tests for pairwise
comparison or linear trend over dose levels.
Results
Expression analysis of NTS signaling components in endogenous or 5-aza-CdR treated CRC cell lines. To assess NTS and
NTSR expression in CRC cells, we performed RT-PCR analysis
of NTS constituents in six human CRC cell lines (KM12c,
Caco2, DLD1, HT29, HCT116 and SW480). Whereas NTSR3
mRNA was consistently expressed in all six cell lines (Fig. 1A),
NTSR2 expression was not observed (data not shown). Selective
expression of NTSR1 and NTS was noted; little to no expression

of NTSR1 was noted in KM12c, Caco2 and DLD1 cells, and
an absence of NTS expression was detected in SW480 cells
(Fig. 1A). Recently, we showed that promoter methylation is
a key mechanism regulating the differential expression of
NTSR1 and to silence NTSR2 in NET cells (16). To confirm
whether the altered expression of NTSR1 and NTSR2 in CRC
cells was a result of DNA methylation, we treated DLD1 and
Caco2 cells with the DNA methyltransferase inhibitor, 5-azaCdR, and evaluated the expression of the NTSRs by RT-PCR
(Fig. 1B). Treatment with 5-aza-CdR augmented the expression
of NTSR1 and NTSR2 in DLD1 and Caco2 cells, respectively.
To verify these results, the level of mRNA expression was also
examined by RT-qPCR (Fig. 1C). Treatment with 5-aza-CdR
resulted in an approximate 54-fold induction of NTSR1 expression in DLD1 and an approximate 4-fold induction in Caco2
cells. Together, these results suggest that NTSR1 and NTSR2
are targets of methylation in CRC cells.
Correlation between gene silencing and promoter methylation of NTSR1 and NTSR2 in CRC cells. To determine whether
induction of NTSR1 and NTSR2 expression by 5-aza-CdR was
due to promoter methylation, we investigated the methylation
status of CpG islands for these genes using methylationspecific PCR (MSP) and bisulfite sequencing. While the
NTSR1/2 promoters were found to be almost completely
methylated in KM12c, Caco2 and DLD1 cells, the NTSR1
promoter in HT29, HCT116 and SW480 cells was shown to be
unmethylated (Fig. 2A). The methylation profile of the CpG
sites of NTSR1 was further analyzed by bisulfite sequencing
(Fig. 2B). Consistent with the MSP data, the CpG islands of
NTSR1 were not methylated in HT29, HCT116 and SW480
cells. Moreover, promoter methylation of NTSR2 was noted in
all six CRC cell lines by MSP analysis (Fig. 2A) and bisulfite
sequencing analyses (Fig. 2C). These data demonstrate that
promoter methylation silences the NTSR1/2 genes.
Knockdown of NTSR1 represses cell growth and migration
in CRC cells. We previously reported that inhibition of NTS
signaling components such as NTS and NTSR1 suppressed
tumorigenic functions in NET cells (16,18). To elucidate the
potential oncogenic functions of NTS components in CRC
cells, small interfering RNA (siRNA) directed against NTSR1,
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Figure 2. Methylation analysis of NTSR1 and NTSR2 promoter regions in CRC cells. (A) MSP analysis of the NTSR1 and NTSR2 promoters in six CRC cell
lines using primers specific for methylated (M) and unmethylated (U) DNA, respectively. (B) Bisulfite genomic sequencing of NTSR1 CpG islands in CRC
cell lines. Each row of circles indicates the DNA sequence of an individual clone; closed and open circles represent methylated and unmethylated CpG sites,
respectively. Bold grey lines are candidate CpG islands detected by Methyl Primer Express Software v1.0 (Applied Biosystems). The arrows below the CpG
islands represent sites of the primers for bisulfite sequencing (thicker) and MSP (thinner), respectively. (C) Bisulfite sequencing analysis of the 5' region of
NTSR2 in the CRC cells; protocol and data presentation are as outlined above.

Figure 3. Silencing of NTSR1 influences cell growth and migration in CRC cells. (A) Equal numbers of HCT116 (left) and HT29 (right) cells transfected with
siRNA against non-targeting (Cont) or NTSR1 were seeded in 24-well plates. Cells were counted after 48 and 96 h incubation using a cell counter. *P<0.05
indicates a significant difference in cell number versus Cont. (B) Analyses of mRNA by RT-PCR (left) and protein by western blot (right) for expression of
IL-8, cyclin D1 and NTSR1 in HCT116 and HT29 cells transfected with Cont or NTSR1 siRNA. β-actin was the loading control. (C) Migration analysis by
wound-healing assay was performed with Cont and NTSR1 knockdown HCT116 cells. Phase-contrast microscopic images (left) show Cont or NTSR1-silenced
cells at 1 h (upper) or 22 h (bottom) after removal of the insert (dark center/cell-free zone). White lines show the cell boundary and the graph (right) provides
quantification of the migrated distance. *P<0.05 indicates a significant difference in migration versus Cont. (D) Migration analysis with Cont and NTSR1
knockdown HT29 cells; protocol and data presentation are as outlined in (C).
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Figure 4. SR48692, an NTSR1 antagonist, decreases CRC cell growth and migration. (A) Equal numbers of HCT116 (left) and HT29 (right) cells were plated
in 24-well plates. One day after seeding, cells were treated with 0 or 10 µM SR48692 for 48 and 96 h; cell numbers were determined using a cell counter.
Significant difference versus vehicle (0 µM) treatments at 48 h (*) and 96 h (†) are indicated, with P<0.05. (B) RT-PCR (upper) and western blot (bottom)
analyses show regulated expressions of IL-8 and cyclin D1 in HCT116 and HT29 cells after SR48692 treatment for 2 days. (C) Graphic representation of the
relative luciferase activity at the IL-8 promoter in HCT116 (left) and HT29 (right) cells treated with SR48692. *P<0.05 indicates a significant difference in
IL-8 promoter activity versus vehicle treatment. (D) Migration analysis using the Boyden chamber with HCT116 cells treated with 10 µM SR48692 or vehicle
(control) for 20 h. Phase-contrast microscopic images (left) and quantification of migrated cells observed in four different fields using an inverted microscope
(right) are shown. *P<0.05 indicates a significant difference in migrated cell number versus control.

which is inconsistently expressed among the tested cell
lines (Fig. 1A), was used in HCT116 and HT29 cells since
these cell lines do express the NTS transcript (Fig. 1A), and
release NTS peptide (19). Knockdown of NTSR1 inhibited
cell growth for 48 and 96 h in both HCT116 and HT29 cells
compared with cells transfected with non-targeting control
siRNA (Fig. 3A). Furthermore, silencing NTSR1 significantly
suppressed mRNA expression of IL-8, which can be induced
by NTS signaling (20) and is associated with tumorigenic
functions in CRC (21) and cyclin D1, which is important for
cell growth (18,22) (Fig. 3B, left). Protein expressions of IL-8
and cyclin D1 were also decreased in cell lines with NTSR1
knockdown (Fig. 3B, right). In addition to cell proliferation,
NTSR1 activation influences cell migration and invasion
in some cancers including breast and NET (13,16,23). On
the basis of these studies, we next assessed the migratory
activity of CRC cells transfected with NTSR1 siRNA using a
wound-healing migration assay. Silencing NTSR1 suppressed
cell migration of HCT116 cells (Fig. 3C) and HT29 cells
(Fig. 3D), respectively. Collectively, these findings suggest
that knockdown of NTSR1 significantly inhibits the growth
and migration of CRC cells.
SR48692, an NTSR1 antagonist, suppresses cell proliferation
and migration of CRC cells. To further delineate the role of

NTSR1, we examined the effect of a pharmacologic blockade of
NTSR1 using SR48692 in HCT116 and HT29 cells. Treatment
with SR48692 repressed proliferation in HCT116 and HT29
cells for 48 and 96 h (Fig. 4A) and reduced both mRNA (upper
panels) and protein expressions (lower panels) of IL-8 and
cyclin D1 in the cell lines (Fig. 4B). Additionally, SR48692
inhibited the promoter activity of IL-8, which promotes tumor
growth, metastasis and angiogenesis in CRC cell lines (21)
(Fig. 4C). Moreover, HCT116 cells treated with SR48692
showed significantly decreased cell migration compared to
vehicle-treated control cells (Fig. 4D). These results confirm
that treatment with a selective NTSR1 antagonist inhibits cell
growth and migration of CRC cells, and is consistent with
results obtained with the siRNA experiments outlined above.
These data indicate that inhibition of NTSR1, either through
gene knockdown or receptor blockade, suppresses the growth
and migration of CRC cells, and demonstrates a role for
NTSR1 in CRC tumorigenesis.
Discussion
It has been reported that NTS and/or NTSR1 are overexpressed
in some types of cancers and many cancer cell lines, and that
inhibition of NTS signaling can suppress the oncogenic activities in several cancer cell lines (10-14,16,23,24). Moreover,
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there is accumulating evidence that NTSR1 activation is
linked with poor prognosis, cancer progression and a higher
incidence of metastases in lung and breast cancers (13,14).
However, the regulatory mechanism directing the expression of NTS pathway components in CRC cells is not
well-delineated. One regulatory process has been proposed;
activation of Wnt/β-catenin signaling plays an essential role
in the upregulation of NTSR1 in CRC (25) and NTS is a
direct target of the Wnt/β-catenin pathway in NET cells (18).
In addition, Dong et al in our laboratory showed that promoter
methylation contributes to the regulation of NTS expression
in human cancer cells including colon cancer (26,27) and we
have also recently demonstrated that promoter methylation is
an important molecular process regulating the expression of
NTSR1 and NTSR2 in NET cells (16). Herein, we observed
diverse expression of NTSR1 and NTS, no expression of
NTSR2, and consistent expression of NTSR3 in the CRC cells
examined in this study. In particular, we speculate that the
varied level of NTS expression (KM12c, Caco2, DLD1, HT29
and HCT116 versus SW480 cells, Fig. 1A) is attributed to
promoter methylation on the basis of our current result and
previous study that DNA methylation is associated with NTS
expression in CRC cells (27). We also found that the gene
expression patterns for NTSR1 and NTSR2 in CRC cells are
similar to those in NET (16) suggesting that promoter methylation of NTS signaling constituents is closely associated with
silencing of the genes in human cancer cells.
In NTS pathway genes (especially NTSR1 and NTSR2)
whose expression was demonstrated to be modulated by
promoter methylation in our study, it has been reported that
activation of NTSR1 induces cell proliferation, migration and
invasion in a variety of cancers (8,11,24). Therefore, we evaluated the role of NTSR1 on cell growth and migration in CRC
cell lines. In previous studies, the effects of NTS-mediated
NTSR1 activation were usually assessed through direct treatment of cancer cells with NTS or an NTS agonist (11,15,23,24).
Herein, we determined the effect of NTSR1 inhibition without
NTS treatment on cell growth and migration in CRC cells.
Previously, NTS expression was reported in some cancer cells
including CRC (11-14); these findings were confirmed in our
present study by RT-PCR analysis (Fig. 1A). In addition, our
group identified NTS peptide secretion in CRC cell lines
including HCT116 and HT29 (19). Analogous to our previous
findings and current study, we find that endogenous NTS can
exert stimulatory properties of cell growth and migration
through NTSR1 in CRC cells through both autocrine and
paracrine pathways.
As aforementioned, it has been reported that a higher level
of NTSR1 expression is observed in several human cancer
tissues such as pancreas, lung, breast, prostate, colon and NET
and that the NTSR1 correlates with tumor progression and
aggressiveness (10-16). These findings suggest that NTSR1
may be a potential diagnostic biomarker and treatment target
for these cancers. However, as noted above, NTSR1 promoter
hypermethylation, which can lead to the gene silencing, was
also found in lung and pancreatic cancers through genome scanning or global DNA methylation profiling, and was identified as
a predictive marker for the cancers (28-30). These intricacies
imply that additional unrevealed adjusters or mechanisms may
affect the level of NTSR1 expression and that further work is
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needed to clarify the detailed machinery between expression
and silencing of NTSR1 in various types of cancer.
In conclusion, our study shows that promoter methylation
is a key regulatory event for NTSR1 and NTSR2 expression in
CRC cells. In addition, we confirmed that inhibition of NTSR1
suppresses cell proliferation and migration in these cells. Our
findings provide a rationale and incentive to explore NTSR1 as
a therapeutic target of CRC growth and pathogenesis.
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